{"product_id":"revvity-pestle-analysis","title":"Revvity PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Competitive Advantage Starts with This Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eNavigate the complex external forces shaping Revvity's trajectory with our comprehensive PESTLE analysis. Understand how political shifts, economic volatility, and technological advancements are creating both opportunities and challenges for the company. Gain a crucial competitive advantage by leveraging these expert-driven insights to refine your own strategic planning. Download the full PESTLE analysis now and unlock actionable intelligence to drive informed decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Funding for R\u0026amp;D Fluctuations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGovernment funding for research and development (R\u0026amp;D) can significantly impact companies like Revvity, whose customers include government and academic institutions. These sectors often exhibit cautious spending patterns due to budget uncertainties, which can directly translate into slower revenue growth for suppliers. For instance, a slowdown in federal research grants can directly affect the demand for life sciences and diagnostics tools.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Policy and Reimbursement Changes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChanges in healthcare policies and reimbursement frameworks, especially in major markets, can significantly influence Revvity's diagnostics segment. For example, evolving hospital lab reimbursement policies in China have contributed to a noticeable slowdown in Revvity's Immunodiagnostics business. These policy shifts directly affect product demand and profitability, necessitating strategic adjustments by Revvity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Trade Policies and Tariffs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGlobal trade dynamics, particularly the implementation of tariffs, directly impact Revvity's international business and its intricate supply chains. For instance, the ongoing trade tensions between major economies can lead to increased costs for imported components or finished goods, affecting profitability.\u003c\/p\u003e\n\u003cp\u003eRevvity has publicly stated its awareness of these challenges, noting the estimated financial impact of specific tariffs, such as those imposed by the US on goods from China. The company is actively developing strategies, including supply chain adjustments and enhanced cost controls, to counter these economic headwinds.\u003c\/p\u003e\n\u003cp\u003eThese trade policies can significantly inflate operational expenses and create barriers to entry or expansion in key global markets. For example, a 25% tariff on critical medical equipment components could add millions in costs, forcing price adjustments or a reassessment of manufacturing locations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Stability and Market Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRevvity's extensive global footprint, spanning over 160 countries, inherently exposes it to a spectrum of geopolitical risks. These risks can significantly impact market stability and the accessibility of its products and services. For instance, the company reported a notable decline in diagnostics product sales in China during 2024, attributed to evolving policy landscapes and local market dynamics. This highlights how shifts in international relations and regulatory environments directly influence Revvity's revenue streams.\u003c\/p\u003e\n\u003cp\u003eNavigating these complexities requires a robust approach to supply chain resilience and the cultivation of diversified market strategies. By not relying too heavily on any single region, Revvity can better mitigate the adverse effects of geopolitical instability. The company's ability to adapt to varying political climates and regulatory frameworks across its operating territories is paramount for sustained global revenue generation and market access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eGeopolitical Exposure:\u003c\/strong\u003e Revvity operates in over 160 countries, making it susceptible to a wide range of geopolitical risks that can disrupt market access and stability.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRegional Challenges:\u003c\/strong\u003e A decline in diagnostics product sales in China during 2024, influenced by policy and market shifts, exemplifies the direct impact of regional geopolitical factors on Revvity's performance.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Imperatives:\u003c\/strong\u003e Ensuring supply chain resilience and implementing diversified market strategies are critical for Revvity to effectively manage geopolitical risks and maintain global revenue generation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Environment and Market Entry Barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe political landscape significantly influences the health technology sector, with government policies on new diagnostic tools directly impacting market entry. Stringent regulatory pathways, such as those managed by the FDA and European authorities, can present substantial hurdles for companies like Revvity. These approval processes, while crucial for patient safety and product validation, often lead to extended timelines for new product introductions.\u003c\/p\u003e\n\u003cp\u003eRevvity's proactive approach to navigating these complexities is evident in its pursuit of approvals for key innovations. For instance, securing FDA clearance for its latent tuberculosis test and obtaining CE Mark certifications for various assays underscore the company's commitment to meeting diverse international regulatory standards. These efforts highlight the critical interplay between political will, regulatory frameworks, and a company's ability to bring advanced health solutions to market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eRegulatory Hurdles:\u003c\/strong\u003e Government policies and strict approval processes create significant barriers to market entry for new health technologies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduct Launch Delays:\u003c\/strong\u003e Lengthy regulatory reviews, while ensuring safety, can delay the commercialization of innovative diagnostic tools.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRevvity's Engagement:\u003c\/strong\u003e Revvity actively seeks FDA clearance and CE Mark approvals, demonstrating continuous adaptation to global regulatory environments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolitical Forces Reshape Healthcare Business\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGovernment funding and healthcare policy shifts are pivotal political forces affecting Revvity. For instance, changes in China's hospital lab reimbursement policies impacted Revvity's Immunodiagnostics business in 2024, illustrating how regulatory adjustments can directly influence revenue. Additionally, trade tensions and tariffs, such as those impacting goods between the US and China, add complexity to global supply chains and operational costs for companies like Revvity.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThis Revvity PESTLE analysis examines the influence of Political, Economic, Social, Technological, Environmental, and Legal factors on the company's operations and strategic positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThe Revvity PESTLE analysis offers a clear, summarized version of complex external factors, making it easy to reference during crucial meetings and presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Economic Growth and Healthcare Spending\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlobal economic growth is a significant driver for Revvity, as it directly impacts healthcare budgets and the research and development (R\u0026amp;D) investments made by pharmaceutical and biotechnology firms, who are Revvity's primary clientele. For instance, the International Monetary Fund (IMF) projected global growth to be 3.2% in 2024, a slight slowdown from 3.5% in 2023, which could translate to more cautious spending by these key customers.\u003c\/p\u003e\n\u003cp\u003eWhile Revvity's Life Sciences segment demonstrated robust organic growth, its diagnostics segment encountered headwinds in specific regions during 2024. Economic downturns or periods of uncertainty often lead to decreased investment in new research initiatives and a general tightening of healthcare expenditures, potentially affecting Revvity's future revenue streams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflation, Operating Margins, and FX Rates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInflationary pressures are a significant concern, directly impacting Revvity's cost of raw materials and overall operational expenses. For instance, in the fiscal year 2023, the company faced these challenges, which contributed to a more complex operating environment.\u003c\/p\u003e\n\u003cp\u003eFluctuations in currency exchange rates, particularly in 2023, have also played a crucial role, affecting Revvity's international revenue streams and overall profitability. The company specifically noted that changes in FX rates, alongside lower volumes of high-margin diagnostic tests, put pressure on its operating margins.\u003c\/p\u003e\n\u003cp\u003eEffectively managing these intertwined economic factors – inflation and FX rates – is absolutely critical for Revvity to maintain and improve its financial performance in the coming periods.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Expenditure Trends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGlobal healthcare spending is a significant driver for companies like Revvity. In 2024, projections indicate continued growth in healthcare expenditure worldwide, driven by aging populations and advancements in medical technology. This generally bodes well for demand in diagnostic and research solutions.\u003c\/p\u003e\n\u003cp\u003eHowever, specific market dynamics can create headwinds. For instance, a slowdown in diagnostic demand in China, partly due to evolving reimbursement policies, has impacted Revvity's outlook. This highlights the need to closely monitor regional expenditure trends and policy changes to ensure market penetration and sustained growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D Investment Cycles in Pharma and Biotech\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe pharmaceutical and biotechnology industries' R\u0026amp;D investment cycles are critical economic engines for Revvity's Life Sciences business.  Despite ongoing macroeconomic headwinds, the sector has demonstrated robust growth, suggesting continued significant investment in the complex processes of drug discovery and development.\u003c\/p\u003e\n\u003cp\u003eThis sustained investment directly benefits companies like Revvity. For instance, Revvity's Signals Software franchise, which plays a crucial role in supporting these R\u0026amp;D endeavors, has seen strong performance. This underscores the direct correlation between R\u0026amp;D spending trends and the demand for Revvity's solutions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eGlobal pharmaceutical R\u0026amp;D spending was projected to reach approximately $240 billion in 2024.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eBiotechnology sector funding, particularly venture capital investment, saw a resurgence in late 2023 and early 2024, after a dip in 2022.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eRevvity reported a 3% increase in its Life Sciences segment revenue for the first quarter of 2024, reaching $725 million, partly driven by demand for R\u0026amp;D enabling technologies.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe average cost to bring a new drug to market continues to be substantial, often exceeding $1 billion, necessitating consistent and substantial R\u0026amp;D investment.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital Allocation and Shareholder Value\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRevvity's capital allocation strategy is a clear indicator of its financial strength and dedication to enhancing shareholder value. The company actively engages in returning capital to shareholders, a move that signals confidence in its ongoing operations and future prospects.\u003c\/p\u003e\n\u003cp\u003eA prime example of this commitment was Revvity's repurchase of nearly $300 million worth of its stock in the second quarter of 2025. This substantial buyback demonstrates a proactive approach to managing its capital structure and rewarding investors.\u003c\/p\u003e\n\u003cp\u003eFurthermore, Revvity prioritizes disciplined capital deployment, ensuring that investments are made strategically while simultaneously maintaining its investment-grade credit rating. This balanced approach allows the company to pursue growth opportunities without compromising its financial stability.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eShare Repurchases:\u003c\/strong\u003e Nearly $300 million in stock repurchased in Q2 2025.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFinancial Health:\u003c\/strong\u003e Reflects strong financial performance and confidence in future growth.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eShareholder Value:\u003c\/strong\u003e A key objective of the company's capital allocation strategy.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCredit Rating:\u003c\/strong\u003e Commitment to maintaining an investment-grade credit rating alongside capital deployment.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEconomic Shifts Shape Healthcare and R\u0026amp;D Investment Landscape\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGlobal economic growth influences healthcare and R\u0026amp;D spending by Revvity's clients. The IMF projected 3.2% global growth for 2024, a slight slowdown that could lead to more cautious client investment. Inflationary pressures in 2023 impacted Revvity's operational costs, and currency fluctuations also affected international revenue and margins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eEconomic Factor\u003c\/th\u003e\n\u003cth\u003eImpact on Revvity\u003c\/th\u003e\n\u003cth\u003eData Point\/Trend\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal Economic Growth\u003c\/td\u003e\n\u003ctd\u003eAffects healthcare budgets and R\u0026amp;D investment\u003c\/td\u003e\n\u003ctd\u003eIMF projected 3.2% global growth for 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInflation\u003c\/td\u003e\n\u003ctd\u003eIncreases raw material and operational costs\u003c\/td\u003e\n\u003ctd\u003eCompany faced challenges in FY2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrency Exchange Rates\u003c\/td\u003e\n\u003ctd\u003eImpacts international revenue and profitability\u003c\/td\u003e\n\u003ctd\u003eFX rates pressured operating margins in 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare Spending\u003c\/td\u003e\n\u003ctd\u003eDrives demand for diagnostics and research solutions\u003c\/td\u003e\n\u003ctd\u003eContinued global growth projected for 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Investment\u003c\/td\u003e\n\u003ctd\u003eCrucial for Life Sciences segment growth\u003c\/td\u003e\n\u003ctd\u003eGlobal pharma R\u0026amp;D spending projected at $240 billion for 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eRevvity PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact document you’ll receive after purchase—fully formatted and ready to use. This comprehensive Revvity PESTLE analysis delves into the Political, Economic, Social, Technological, Legal, and Environmental factors impacting the company, providing a robust strategic overview.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":55296206045532,"sku":"revvity-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/revvity-pestle-analysis.png?v=1755778586","url":"https:\/\/pestel-analysis.com\/products\/revvity-pestle-analysis","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}